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One of the most widely pursued therapeutic strategies in cancer
therapy has been to target the angiogenic process in tumour
progression. Angiogenesis is the process by which a solid tumour
develops its own blood supply by hijacking the surrounding
vasculature to invade the growing tumour mass. Angiogenesis is
essential for solid tumours to grow beyond the microscopic level
and metastasise. Since the seminal discoveries made on angiogen-
esis by Judah Folkman over three decades ago, angiogenesis has
been hotly pursued as a therapeutic target in cancer. Despite this,
to date, there is no effective antiangiogenic agent that can be used
as a single agent in the clinic. The editors of Antiangiogenic Cancer
Therapy have recognised the timeliness of such a book. This book
provides a detailed and comprehensive overview of Antiangiogenic
Cancer Therapy; past, present and future, making this book an
important source for researchers and clinicians working in this
area of cancer biology.
Antiangiogenic Cancer Therapy contains over 840 pages of text
from 79 expert and authoritative international academic and
industrial scientists and clinicians. The book is divided into four
themed parts (I–IV), 1: angiogenesis and cancer, II: targeting
angiogenesis for cancer therapy, III: translating angiogenesis
inhibitors to the clinic and IV: treatment of specific cancers with
angiogenesis inhibitors. Each part is subdivided into several
chapters relevant to the theme and written by well-recognised
experts on the topic of the chapter. The book spans 32 chapters.
Each chapter is a comprehensive stand-alone review, including
a detailed content section, an introductory discussion section, a
conclusion/summary section and a comprehensive bibliography.
This format allows the reader to access information in its entirety
on a given topic and is aided by a very useful index at the back of
the book. One minor drawback to this format is that there is some
repetition, which is inevitable given the topics covered and the
extensive nature of this book. The book benefits from a multitude
of helpful summary tables, beautiful illustrations and drawings
throughout and a section of colour figures in the centre of the
book.
Part I of Antiangiogenic Cancer Therapy contains five chapters
and provides a detailed background to angiogenesis in cancer as a
basis for the proceeding parts. Chapter 1 is an interesting first
chapter that discusses strategies to prolong the non-angiogenic
dormant state of human cancers. Dormant tumours are
pre-angiogenic where cells exhibit balanced apoptosis and
proliferation. Interestingly, this chapter looks at imaging of
dormant tumours and discusses molecular mechanisms and
biomarkers for the angiogenic switch, metastatic dormancy and
induction of dormancy using antiangiogeneic therapies. Chapter 2
follows by reviewing vascular endothelial growth factor (VEGF):
basic biology and clinical implications in extensive detail. This
chapter provides a background to VEGF and VEGF receptor
biology, and discusses the role of VEGF signalling in physiological
angiogenesis and pathological conditions, such as cancer and
intraocular neovascular syndromes. The third chapter discusses
angiogenesis in solid tumours and contains several informative
3-dimensional illustrations and excellent images of tumour blood
vessels. Chapter 4 covers the pathophysiological role of VEGF in
haematological malignancies and follows on very nicely from the
earlier chapter. The final chapter of part I, chapter 5, discusses the
tumour microenvironment and angiogenesis and includes an
informative section on cancer metastasis.
Part II of Antiangiogenic Cancer Therapy introduces strategies
involved in targeting angiogenesis for cancer therapy and spans 12
chapters. The second part starts with chapter 6, which provides a
comprehensive review of tyrosine kinase inhibitors of angiogenesis
and other multi-targeted agents, and is concluded by providing an
informative perspective section. Chapter 7 deals with the devel-
opment of antiangiogenic monoclonal antibodies for cancer
therapy. This chapter provides a detailed background on antibody
structure, discovery and engineering, describes the mechanism of
action of antibody-based therapy and provides an informative
section on the VEGF/VEGFR pathway and the effects of mono-
clonal VEGF antibody therapy (bevacizumab) in colorectal, lung,
renal and breast cancer. Chapter 8 follows by focusing on FGF and
the FGFR system in angiogenesis and includes both signal
transduction inhibitors and dominant-negative signalling mole-
cules. Chapter 9 covers the development of VEGF trap as a novel
antiangiogenic therapy and discusses its promising preclinical
evaluation in cancer models and potential use for vascular eye
disease. There is some overlap in this chapter with some of the
earlier chapters (e.g., VEGF biology). Interestingly, this chapter
concludes by discussing the next generation targets in angiogen-
esis including angiopoietins and DII4. Chapter 10 follows with a
detailed look at proteinases and their inhibitors in angiogenesis.
A comprehensive list of metalloproteinase (MMP) inhibitor agents
in the clinic (phase I–III stages) and other small molecule
inhibitors (e.g., against ADAM-10) is included. This chapter also
provides a transparent overview of the disappointing performance
of MMP inhibitors in clinical trials. Chapter 11 focuses on prosta-
glandins and COX-2 and their role in antiangiogenic therapy.
A useful table is included with the outcomes for various combi-
nation treatments (cytotoxic agent or a small molecule agent) with
celecoxib (COX-2 inhibitor) in breast, lung, colon, pancreatic and
oesophageal cancers. The role of COX-2 inhibitors in cancer treat-
ment remains uncertain, and the chapter concludes with a helpful
section on future directions for these agents. Chapter 12 discusses
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This chapter includes a thorough background on the biology of the
extracellular matrix (ECM) and the integrin family, and discusses
the current status on targeting various types of integrins, for
example, collagen-binding, laminin-binding, fibronectin-binding
and the effects on angiogenesis. Chapter 13 provides an overview
of conventional therapies with antiangiogenic activity. This
chapter has some overlap with other chapters, but interestingly
describes the PPAR family and inhibitors, effects of mTOR
inhibitors, metronomic dosing in chemotherapy and discusses
the need for combined treatment regimes when using antiangio-
genic agents. Chapter 14 deals with vascular disrupting agents
(VDAs) in preclinical and clinical (phase I/II) development either
as single agents or in combination with radiotherapy and
conventional drugs. This chapter also addresses gene therapy
and ligand-based approaches to targeting the vasculature. An
interesting chapter follows (chapter 15) on vascular and haema-
topoietic stem cells as targets for antiangiogenic therapy. Chapter
16 describes genetic strategies for targeting angiogenesis and
discusses the utilisation of microarray techniques to identify
downstream and upstream modulator/regulators of angiogenesis.
There are several detailed sections on gene therapy-mediated
delivery systems in this chapter and an excellent section on future
considerations, recommendations and conclusions relating to this
chapter’s topic. Chapter 17 covers the identification of new targets
using expression profiles with several sections including; a section
on expression profiling methods, computational analysis of
expression profiling data and validation of expression profiles.
This chapter concludes very positively with a section on success
stories in the field.
Part III of Antiangiogenic Cancer Therapy provides an overview
of translating angiogenesis inhibitors into the clinic, including
translational and clinical trial design for effective treatment using
angiogenesis inhibitors. Part III starts with chapter 18, which
provides background to the Federal Drug Administration (FDA)
oversight of clinical trials, and includes details on the requirement
for demonstration of safety and efficacy, important oncology end
points, and has an informative section on the use of targeted
therapies versus conventional cytotoxics. Chapter 19 follows, and is
an important chapter, which describes surrogate markers for
antiangiogeneic cancer therapy and their rationale, including the
use and identification of markers in serum, plasma, urine and
tumour biopsies and ex vivo markers. This chapter compliments
the next chapter, chapter 20, which provides a detailed overview of
non-invasive surrogates, and includes sections on general imaging
and types of measurements, indirect measurements of vascularity
and blood flow, a discussion of blood flow measurements and
indirect tests not measuring blood flow (e.g., MR spectroscopy,
diffusion-weighted MRI and radionuclide imaging), and details
on specific (direct) imaging and current developments. This
chapter has an excellent conclusions and perspectives section
at the end that includes key questions regarding the role of
imaging in therapy. The theme of markers continues into chapter
21, which discusses pharmacodynamic (PD) markers in tissues,
including direct and indirect PD analysis of angiogenesis
inhibitors and multi-targeted agents. This chapter contains several
informative tables that summarise PD markers in tumours and
concludes with a section on challenges and perspectives. The final
chapter of part III, chapter 22 discusses blood-based biomarkers
for VEGF inhibitors, outlines the importance of identifying and
analysing suitable biomarkers and describes various marker types,
such as soluble markers, endothelial cell markers, cellular markers
in peripheral blood and markers found within other cell
populations. The chapter concludes with a helpful future
directions section.
Part IV of Antiangiogenic Cancer Therapy provides several
comprehensive chapters (23–32) on the treatment of specific
cancers with angiogenic inhibitors. Each chapter reviews a
different cancer type, including colorectal, rectal, breast, lung and
prostate cancer, haematological malignancies, glioma, Kaposi’s
sarcoma and melanoma. The final chapter discusses the treatment
of renal cell carcinoma (RCC) with sunitinib, which is regarded
as the new reference standard for the first-line treatment for RCC.
It is slightly disappointing that there is no overall conclusion
section at the end of the book. Several key conclusions are
reiterated in the final chapters of Antiangiogenic Cancer Therapy
that are echoed throughout the book, (a) there are limitations to
antiangiogenic therapy in many cancers, and currently, most
antiangiogenic agents need to be used in combination with other
agents and (b) there is an increasing need for valid markers of
response, improved imaging and the development of non-invasive
methods for detecting response.
In summary, Antiangiogenic Cancer Therapy is a comprehensive
book that has detailed and expertly written chapters, useful tables
and beautiful illustrations. The book is excellently edited. There is
absolutely no doubt that Antiangiogenic Cancer Therapy is an
important and timely contribution to the field that is applicable to
scientists and clinicians alike.
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